Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of aberrant cell cycle diseases: An update

The Scientific World Journal

Volumn 2012, Issue , 2012, Pages

  Liu, Da Zhi ^a   Ander, Bradley P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 1 (4 METHOXYBENZYL) 3 (5 NITRO 2 THIAZOLYL)UREA; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; 6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; 7 HYDROXYSTAUROSPORINE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; AT 7519; AZD 5438; BMS 200261; BRYOSTATIN 1; CEFTRIAXONE; CELECOXIB; CEP 1347; DINACICLIB; DISUFENTON SODIUM; DIZOCILPINE; FLAVOPIRIDOL; FLUNARIZINE; GSK 2126458; GSK 2141795; INDISULAM; ISOLIQUIRITIGENIN; KX 01; KYS 05090; L 803; MELATONIN; MEMANTINE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; N(G) NITROARGININE METHYL ESTER; NORPHENAZONE; OLOMOUCINE; PBI 05204; QUINAZOLINE DERIVATIVE; RILUZOLE; ROFECOXIB; ROSCOVITINE; RWJ 58259; RX 0201; SCH 79797; SG 410; SUPEROXIDE DISMUTASE; TALAMPANEL; TROLOX C; TRX 0014; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; CYCLIN DEPENDENT KINASE; PROTEIN KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; HUMAN; MITOGENESIS; NEOPLASM; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; REVIEW; COGNITION; DRUG ANTAGONISM; DRUG EFFECT;

CELL CYCLE; CENTRAL NERVOUS SYSTEM DISEASES; COGNITION; CYCLIN-DEPENDENT KINASES; HUMANS; NEOPLASMS; NEUROGENESIS; PROTEIN KINASE INHIBITORS;

EID: 84861063454     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/2012/491737     Document Type: Review

References (250)

1. Liu D. Z., Ander B. P., Sharp F. R., Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of central nervous system diseases Neurobiology of Disease 2010 37 3 549 557
2. Novak B., Tyson J. J., Gyorffy B., Csikasz-Nagy A., Irreversible cell-cycle transitions are due to systems-level feedback Nature Cell Biology 2007 9 7 724 728
3. Norbury C., Nurse P., Animal cell cycles and their control Annual Review of Biochemistry 1992 61 441 470
4. Malumbres M., Barbacid M., To cycle or not to cycle: a critical decision in cancer Nature Reviews Cancer 2001 1 3 222 231
5. Schwartz G. K., Shah M. A., Targeting the cell cycle: a new approach to cancer therapy Journal of Clinical Oncology 2005 23 36 9408 9421
6. Erickson S., Sangfelt O., Heyman M., Castro J., Einhorn S., Grandér D., Involvement of the Ink4 proteins p16 and p15 in T-lymphocyte senescence Oncogene 1998 17 5 595 602
7. Shapiro G. I., Koestner D. A., Matranga C. B., Rollins B. J., Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines Clinical Cancer Research 1999 5 10 2925 2938
8. Chien M., Astumian M., Liebowitz D., Rinker-Schaeffer C., Stadler W. M., In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer Cancer Chemotherapy and Pharmacology 1999 44 1 81 87
9. Schwartz G. K., Farsi K., Maslak P., Kelsen D. P., Spriggs D., Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells Clinical Cancer Research 1997 3 9 1467 1472
10. Arguello F., Alexander M., Sterry J. A., Tudor G., Smith E. M., Kalavar N. T., Greene J. F., Koss W., Morgan C. D., Stinson S. F., Siford T. J., Alvord W. G., Klabansky R. L., Sausville E. A., Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts Blood 1998 91 7 2482 2490
11. Drees M., Dengler W. A., Roth T., Labonte H., Mayo J., Malspeis L., Grever M., Sausville E. A., Fiebig H. H., Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells Clinical Cancer Research 1997 3 2 273 279
12. Tirado O. M., Mateo-Lozano S., Notario V., Roscovitine is an effective inducer of apoptosis of Ewing's sarcoma family tumor cells in vitro and in vivo Cancer Research 2005 65 20 9320 9327
13. Wyatt P. G., Woodhead A. J., Berdini V., Boulstridge J. A., Carr M. G., Cross D. M., Davis D. J., Devine L. A., Early T. R., Feltell R. E., Lewis E. J., McMenamin R. L., Navarro E. F., O'Brien M. A., O'Reilly M., Reule M., Saxty G., Seavers L. C. A., Smith D. M., Squires M. S., Trewartha G., Walker M. T., Woolford A. J. A., Identification of N-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1H- pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design Journal of Medicinal Chemistry 2008 51 16 4986 4999
14. Senderowicz A. M., Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials Investigational New Drugs 1999 17 3 313 320
15. Whittaker S. R., Te Poele R. H., Chan F., Linardopoulos S., Walton M. I., Garrett M. D., Workman P., The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis Cell Cycle 2007 6 24 3114 3131
16. Senderowicz A. M., Sausville E. A., Preclinical and clinical development of cyclin-dependent kinase modulators Journal of the National Cancer Institute 2000 92 5 376 387
17. Dickson M. A., Schwartz G. K., Development of cell-cycle inhibitors for cancer therapy Current Oncology 2009 16 2 36 43
18. Copani A., Ubertia D., Sortino M. A., Bruno V., Nicoletti F., Memo M., Activation of cell-cycle-associated proteins in neuronal death: a mandatory or dispensable path? Trends in Neurosciences 2001 24 1 25 31
19. Verdaguer E., Jord E. G., Canudas A. M., Jiménez A., Pubill D., Escubedo E., Camarasa J., Palls M., Camins A., Antiapoptotic effects of roscovitine in cerebellar granule cells deprived of serum and potassium: a cell cycle-related mechanism Neurochemistry International 2004 44 4 251 261
20. Jorda E. G., Verdaguer E., Canudas A. M., Jiménez A., Bruna A., Caelles C., Bravo R., Escubedo E., Pubill D., Camarasa J., Palls M., Camins A., Neuroprotective action of flavopiridol, a cyclin-dependent kinase inhibitor, in colchicine-induced apoptosis Neuropharmacology 2003 45 5 672 683
21. Kruman I., Schwartz E., Methods of neuroprotection by cyclin-dependent kinase inhibition. US 20080182853, 2006
22. Barvian M. R., Dobrusin E. M., Kaltenbronn J. S., Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes. US 6982260, 2006
23. Osuga H., Osuga S., Wang F., Fetni R., Hogan M. J., Slack R. S., Hakim A. M., Ikeda J. E., Park D. S., Cyclin-dependent kinases as a therapeutic target for stroke Proceedings of the National Academy of Sciences of the United States of America 2000 97 18 10254 10259
24. Wang F., Corbett D., Osuga H., Osuga S., Ikeda J. E., Slack R. S., Hogan M. J., Hakim A. M., Park D. S., Inhibition of cyclin-dependent kinases improves CA1 neuronal survival and behavioral performance after global ischemia in the rat Journal of Cerebral Blood Flow and Metabolism 2002 22 2 171 182
25. Di Giovanni S., Movsesyan V., Ahmed F., Cernak I., Schinelli S., Stoica B., Faden A. I., Cell cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury Proceedings of the National Academy of Sciences of the United States of America 2005 102 23 8333 8338
26. Hilton G. D., Stoica B. A., Byrnes K. R., Faden A. I., Roscovitine reduces neuronal loss, glial activation, and neurologic deficits after brain trauma Journal of Cerebral Blood Flow and Metabolism 2008 28 11 1845 1859
27. Di Giovanni S., Knoblach S. M., Brandoli C., Aden S. A., Hoffman E. P., Faden A. I., Gene profiling in spinal cord injury shows role of cell cycle neuronal death Annals of Neurology 2003 53 4 454 468
28. Tian D. S., Yu Z. Y., Xie M. J., Bu B. T., Witte O. W., Wang W., Suppression of astroglial scar formation and enhanced axonal regeneration associated with functional recovery in a spinal cord injury rat model by the cell cycle inhibitor olomoucine Journal of Neuroscience Research 2006 84 5 1053 1063
29. Park D. S., Obeidat A., Giovanni A., Greene L. A., Cell cycle regulators in neuronal death evoked by excitotoxic stress: implications for neurodegeneration and its treatment Neurobiology of Aging 2000 21 6 771 781
30. Verdaguer E., Jiménez A., Canudas A. M., Jord E. G., Sureda F. X., Palls M., Camins A., Inhibition of cell cycle pathway by flavopiridol promotes survival of cerebellar granule cells after an excitotoxic treatment Journal of Pharmacology and Experimental Therapeutics 2004 308 2 609 616
31. Verdaguer E., Jord E. G., Canudas A. M., Jiménez A., Sureda F. X., Rimbau V., Pubill D., Escubedo E., Camarasa J., Palls M., Camins A., 3-Amino thioacridone, a selective cyclin-dependent kinase 4 inhibitor, attenuates kainic acid-induced apoptosis in neurons Neuroscience 2003 120 3 599 603
32. Verdaguer E., Jord E. G., Stranges A., Canudas A. M., Jiménez A., Sureda F. X., Palls M., Camins A., Inhibition of CDKs: a strategy for preventing kainic acid-induced apoptosis in neurons Annals of the New York Academy of Sciences 2003 1010 671 674
33. Lefvre K., Clarke P. G. H., Danthe E. E., Castagné V., Involvement of cyclin-dependent kinases in axotomy-induced retinal ganglion cell death Journal of Comparative Neurology 2002 447 1 72 81
34. Roe C. M., Behrens M. I., Xiong C., Miller J. P., Morris J. C., Alzheimer disease and cancer Neurology 2005 64 5 895 898
35. Bennett D. A., Is there a link between cancer and Alzheimer disease? Neurology 2010 75 13 1216 1217
36. Becker C., Brobert G. P., Johansson S., Jick S. S., Meier C. R., Cancer risk in association with Parkinson disease: a population-based study Parkinsonism and Related Disorders 2010 16 3 186 190
37. Srensen S. A., Fenger K., Olsen J. H., Significantly lower incidence of cancer among patients with Huntington disease: an apoptotic effect of an expanded polyglutamine tract? Cancer 1999 86 7 1342 1346
38. Hofer S., Linnebank M., Weller M., Cancer risk among patients with multiple sclerosis and their parents Neurology 2010 74 7 614 615
39. Clements C. M., McNally R. S., Conti B. J., Mak T. W., Ting J. P. Y., DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2 Proceedings of the National Academy of Sciences of the United States of America 2006 103 41 15091 15096
40. Zanetti R., Rosso S., Loria D. I., Parkinson's disease and cancer Cancer Epidemiology Biomarkers and Prevention 2007 16 6 1081
41. Bajaj A., Driver J. A., Schernhammer E. S., Parkinson's disease and cancer risk: a systematic review and meta-analysis Cancer Causes and Control 2010 21 5 697 707
42. Ferreira J. J., Neutel D., Mestre T., Coelho M., Rosa M. M., Rascol O., Sampaio C., Skin cancer and Parkinson's disease Movement Disorders 2010 25 2 139 148
43. Garber K., Parkinson's disease and cancer: the unexplored connection Journal of the National Cancer Institute 2010 102 6 371 374
44. Ren H., Fu K., Mu C., Li B., Wang D., Wang G., DJ-1, a cancer and Parkinson's disease associated protein, regulates autophagy through JNK pathway in cancer cells Cancer Letters 2010 297 1 101 108
45. Crespi B., Autism and cancer risk Autism Research 2011 4 302 310
46. Sund R., Pukkala E., Patja K., Cancer incidence among persons with fragile X syndrome in Finland: a population-based study Journal of Intellectual Disability Research 2009 53 1 85 90
47. Bartkova J., Zemanova M., Bartek J., Expression of CDK7/CAK in normal and tumour cells of diverse histogenesis, cell-cycle position and differentiation International Journal of Cancer 1996 66 6 732 737
48. Ishikaw M., Ogihara Y., Miura M., Visualization of radiation-induced cell cycle-associated events in tumor cells expressing the fusion protein of Azami Green and the destruction box of human Geminin Biochemical and Biophysical Research Communications 2009 389 3 426 430
49. Smith P. J., Marquez N., Wiltshire M., Chappell S., Njoh K., Campbell L., Khan I. A., Silvestre O., Errington R. J., Mitotic bypass via an occult cell cycle phase following DNA topoisomerase II inhibition in p53 functional human tumor cells Cell Cycle 2007 6 16 2071 2081
50. Nagy Z., Esiri M. M., Cato A. M., Smith A. D., Cell cycle markers in the hippocampus in Alzheimer's disease Acta Neuropathologica 1997 94 1 6 15
51. McShea A., Harris P. L. R., Webster K. R., Wahl A. F., Smith M. A., Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease American Journal of Pathology 1997 150 6 1933 1939
52. Busser J., Geldmacher D. S., Herrup K., Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain Journal of Neuroscience 1998 18 8 2801 2807
53. Yang Y., Geldmacher D. S., Herrup K., DNA replication precedes neuronal cell death in Alzheimer's disease Journal of Neuroscience 2001 21 8 2661 2668
54. Yang Y., Mufson E. J., Herrup K., Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease Journal of Neuroscience 2003 23 7 2557 2563
55. Jordan-Sciutto K. L., Dorsey R., Chalovich E. M., Hammond R. R., Achim C. L., Expression patterns of retinoblastoma protein in Parkinson disease Journal of Neuropathology and Experimental Neurology 2003 62 1 68 74
56. Nagy Z., Esiri M. M., Neuronal cyclin expression in the hippocampus in temporal lobe epilepsy Experimental Neurology 1998 150 2 240 247
57. Ranganathan S., Bowser R., Alterations in G1 to S phase cell-cycle regulators during amyotrophic lateral sclerosis American Journal of Pathology 2003 162 3 823 835
58. Herrup K., Neve R., Ackerman S. L., Copani A., Divide and die: cell cycle events as triggers of nerve cell death Journal of Neuroscience 2004 24 42 9232 9239
59. Yang Y., Varvel N. H., Lamb B. T., Herrup K., Ectopic cell cycle events link human Alzheimer's disease and amyloid precursor protein transgenic mouse models Journal of Neuroscience 2006 26 3 775 784
60. Khurana V., Lu Y., Steinhilb M. L., Oldham S., Shulman J. M., Feany M. B., TOR-mediated cell-cycle activation causes neurodegeneration in a Drosophila tauopathy model Current Biology 2006 16 3 230 241
61. Nguyen M. D., Boudreau M., Kriz J., Couillard-Després S., Kaplan D. R., Julien J. P., Cell cycle regulators in the neuronal death pathway of amyotrophic lateral sclerosis caused by mutant superoxide dismutase 1 Journal of Neuroscience 2003 23 6 2131 2140
62. Imai H., Harland J., McCulloch J., Graham D. I., Brown S. M., Macrae I. M., Specific expression of the cell cycle regulation proteins, GADD34 and PCNA, in the peri-infarct zone after focal cerebral ischaemia in the rat European Journal of Neuroscience 2002 15 12 1929 1936
63. O'Hare M., Wang F., Park D. S., Cyclin-dependent kinases as potential targets to improve stroke outcome Pharmacology and Therapeutics 2002 93 2-3 135 143
64. Kuan C. Y., Schloemer A. J., Lu A., Burns K. A., Weng W. L., Williams M. T., Strauss K. I., Vorhees C. V., Flavell R. A., Davis R. I., Sharp F. R., Rakic P., Hypoxia-ischemia induces DNA synthesis without cell proliferation in dying neurons in adult rodent brain Journal of Neuroscience 2004 24 47 10763 10772
65. Veeriah S., Taylor B. S., Meng S., Fang F., Yilmaz E., Vivanco I., Janakiraman M., Schultz N., Hanrahan A. J., Pao W., Ladanyi M., Sander C., Heguy A., Holland E. C., Paty P. B., Mischel P. S., Liau L., Cloughesy T. F., Mellinghoff I. K., Solit D. B., Chan T. A., Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies Nature Genetics 2010 42 1 77 82
66. Park D. S., Farinell S. E., Greene L. A., Inhibitors of cyclin-dependent kinases promote survival of post-mitotic neuronally differentiated PC12 cells and sympathetic neurons Journal of Biological Chemistry 1996 271 14 8161 8169
67. Park D. S., Morris E. J., Greene L. A., Geller H. M., G1/S cell cycle blockers and inhibitors of cyclin-dependent kinases suppress camptothecin-induced neuronal apoptosis Journal of Neuroscience 1997 17 4 1256 1270
68. Copani A., Condorelli F., Caruso A., Vancheri C., Sala A., Giuffrida Stella A. M., Canonico P. L., Nicoletti F., Sortino M. A., Mitotic signaling by -amyloid causes neuronal death FASEB Journal 1999 13 2225 2234
69. Varvel N. H., Bhaskar K., Patil A. R., Pimplikar S. W., Herrup K., Lamb B. T., A oligomers induce neuronal cell cycle events in Alzheimer's disease Journal of Neuroscience 2008 28 43 10786 10793
70. Williamson R., Scales T., Clark B. R., Gibb G., Hugh Reynolds C., Kellie S., Bird I. N., Varndell I. M., Sheppard P. W., Everall I., Anderton B. H., Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid- peptide exposure: involvement of Src family protein kinases Journal of Neuroscience 2002 22 1 10 20
71. Wang H., Reiser G., Thrombin signaling in the brain: the role of protease-activated receptors Biological Chemistry 2003 384 2 193 202
72. Ohnishi M., Katsuki H., Fujimoto S., Takagi M., Kume T., Akaike A., Involvement of thrombin and mitogen-activated protein kinase pathways in hemorrhagic brain injury Experimental Neurology 2007 206 1 43 52
73. Guan J., Luo Y., Denker B. M., Purkinje cell protein-2 (Pcp2) stimulates differentiation in PC12 cells by G -mediated activation of Ras and p38 MAPK Biochemical Journal 2005 392 2 389 397
74. Segarra J., Balenci L., Drenth T., Maina F., Lamballe F., Combined signaling through ERK, PI3K/AKT, and RAC1/p38 is required for Met-triggered cortical neuron migration Journal of Biological Chemistry 2006 281 8 4771 4778
75. Lopez-Bergami P., Ronai Z., Requirements for PKC-augmented JNK activation by MKK4/7 International Journal of Biochemistry and Cell Biology 2008 40 5 1055 1064
76. Dwivedi Y., Pandey G. N., Effects of treatment with haloperidol, chlorpromazine, and clozapine on protein kinase C (PKC) and phosphoinositide- specific phospholipase C (PI-PLC) activity and on mRNA and protein expression of PKC and PLC isozymes in rat brain Journal of Pharmacology and Experimental Therapeutics 1999 291 2 688 704
77. Zhu X., Rottkamp C. A., Boux H., Takeda A., Perry G., Smith M. A., Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease Journal of Neuropathology and Experimental Neurology 2000 59 10 880 888
78. Xing B., Xin T., Hunter R. L., Bing G., Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/ Akt Journal of Neuroinflammation 2008 5, article 4
79. Tan J., Neurodegenerative disease treatment using jAK/STAT inhibition. PCT/US2008/055646, 2008
80. Goody R. J., Beckham J. D., Rubtsova K., Tyler K. L., JAK-STAT signaling pathways are activated in the brain following reovirus infection Journal of NeuroVirology 2007 13 4 373 383
81. Li N., Wang C., Wu Y., Liu X., Cao X., Ca2+/calmodulin-dependent protein kinase II promotes cell cycle progression by directly activating MEK1 and subsequently modulating p27 phosphorylation Journal of Biological Chemistry 2009 284 5 3021 3027
82. Mao L. M., Tang Q. S., Wang J. Q., Regulation of extracellular signal-regulated kinase phosphorylation in cultured rat striatal neurons Brain Research Bulletin 2009 78 6 328 334
83. De Bernardo S., Canals S., Casarejos M. J., Solano R. M., Menendez J., Mena M. A., Role of extracellular signal-regulated protein kinase in neuronal cell death induced by glutathione depletion in neuron/glia mesencephalic cultures Journal of Neurochemistry 2004 91 3 667 682
84. Copani A., Nicoletti F., Cell-Cycle Mechanisms and Neuronal Cell Death 2005 New York, NY, USA Kluwer Academic Publishers/Plenum
85. Qian J. Y., Leung A., Harding P., LaPointe M. C., PGE2 stimulates human brain natriuretic peptide expression via EP4 and p42/44 MAPK American Journal of Physiology 2006 290 5 H1740 H1746
86. Fiebich B. L., Schleicher S., Spleiss O., Czygan M., Hll M., Mechanisms of prostaglandin E2-induced interleukin-6 release in astrocytes: possible involvement of EP4-like receptors, p38 mitogen-activated protein kinase and protein kinase C Journal of Neurochemistry 2001 79 5 950 958
87. Darmoul D., Gratio V., Devaud H., Lehy T., Laburthe M., Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells American Journal of Pathology 2003 162 5 1503 1513
88. Traby L., Kaider A., Schmid R., Kranz A., Quehenberger P., Kyrle P. A., Eichinger S., The effects of low-molecular-weight heparin at two different dosages on thrombin generation in cancer patients: a randomised controlled trial Thrombosis and Haemostasis 2010 104 1 92 99
89. Snyder K. M., Kessler C. M., The pivotal role of thrombin in cancer biology and tumorigenesis Seminars in Thrombosis and Hemostasis 2008 34 8 734 741
90. Wang H., Reiser G., The role of the Ca2+-sensitive tyrosine kinase Pyk2 and Src in thrombin signalling in rat astrocytes Journal of Neurochemistry 2003 84 6 1349 1357
91. Liu D. Z., Cheng X. Y., Ander B. P., Xu H., Davis R. R., Gregg J. P., Sharp F. R., Src kinase inhibition decreases thrombin-induced injury and cell cycle re-entry in striatal neurons Neurobiology of Disease 2008 30 2 201 211
92. Fujimoto S., Katsuki H., Ohnishi M., Takagi M., Kume T., Akaike A., Thrombin induces striatal neurotoxicity depending on mitogen-activated protein kinase pathways in vivo Neuroscience 2007 144 2 694 701
93. Driessens G., Harsan L., Browaeys P., Giannakopoulos X., Velu T., Bruyns C., Assessment of in vivo chemotherapy-induced DNa damage in a p53-mutated rat tumor by micronuclei assay Annals of the New York Academy of Sciences 2003 1010 775 779
94. Van Kaick G., Delorme S., Therapy-induced effects in normal tissue Radiologe 2008 48 9 871 880
95. Lucas K., Gula M. J., Blatt J., Relapse in acute lymphoblastic leukemia as a function of white blood cell and absolute neutrophil counts during maintenance chemotherapy Pediatric Hematology and Oncology 1992 9 2 91 97
96. Wefel J. S., Saleeba A. K., Buzdar A. U., Meyers C. A., Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer Cancer 2010 116 14 3348 3356
97. Harrington C. B., Hansen J. A., Moskowitz M., Todd B. L., Feuerstein M., It's not over when it's over: long-term symptoms in cancer survivorsa systematic review International Journal of Psychiatry in Medicine 2010 40 2 163 181
98. Dietrich J., Monje M., Wefel J., Meyers C., Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy Oncologist 2008 13 12 1285 1295
99. Taphoorn M. J. B., Klein M., Cognitive deficits in adult patients with brain tumours Lancet Neurology 2004 3 3 159 168
100. Byrne T. N., Cognitive sequelae of brain tumor treatment Current Opinion in Neurology 2005 18 6 662 666
101. Brire M.-E., Scott J. G., McNall-Knapp R. Y., Adams R. L., Cognitive outcome in pediatric brain tumor survivors: delayed attention deficit at long-term follow-up Pediatric Blood and Cancer 2008 50 2 337 340
102. Hilverda K., Bosma I., Heimans J. J., Postma T. J., Peter Vandertop W., Slotman B. J., Buter J., Reijneveld J. C., Klein M., Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings Journal of Neuro-Oncology 2010 97 1 89 94
103. Talacchi A., Santini B., Savazzi S., Gerosa M., Cognitive effects of tumour and surgical treatment in glioma patients Journal of Neuro-Oncology 2010 103 3 541 549
104. Correa D. D., Cognitive functions in brain tumor patients Hematology/Oncology Clinics of North America 2006 20 6 1363 1376
105. Marsh J. C., Gielda B. T., Herskovic A. M., Abrams R. A., Cognitive sparing during the administration of whole brain radiotherapy and prophylactic cranial irradiation: current concepts and approaches Journal of Oncology 2010 2010 16
106. Brandt M. D., Storch A., Neurogenesis in the adult brain: from bench to bedside? Fortschritte der Neurologie Psychiatrie 2008 76 9 517 529
107. Shen J., Xie L., Mao X., Zhou Y., Zhan R., Greenberg D. A., Jin K., Neurogenesis after primary intracerebral hemorrhage in adult human brain Journal of Cerebral Blood Flow and Metabolism 2008 28 8 1460 1468
108. Neundrfer B., Does the neurogenesis in the adult brain show the way into the future? Fortschritte der Neurologie Psychiatrie 2008 76 9 511
109. Liu J., Solway K., Messing R. O., Sharp F. R., Increased neurogenesis in the dentate gyrus after transient global ischemia in gerbils Journal of Neuroscience 1998 18 19 7768 7778
110. Abdipranoto A., Wu S., Stayte S., Vissel B., The role of neurogenesis in neurodegenerative diseases and its implications for therapeutic development CNS and Neurological Disorders 2008 7 2 187 210
111. Chesnokova V., Pechnick R. N., Antidepressants and Cdk inhibitors: releasing the brake on neurogenesis? Cell Cycle 2008 7 15 2321 2326
112. Ohab J. J., Fleming S., Blesch A., Carmichael S. T., A neurovascular niche for neurogenesis after stroke Journal of Neuroscience 2006 26 50 13007 13016
113. Palmer T. D., Willhoite A. R., Gage F. H., Vascular niche for adult hippocampal neurogenesis Journal of Comparative Neurology 2000 425 4 479 494
114. Eriksson P. S., Perfilieva E., Bjrk-Eriksson T., Alborn A. M., Nordborg C., Peterson D. A., Gage F. H., Neurogenesis in the adult human hippocampus Nature Medicine 1998 4 11 1313 1317
115. Roy N. S., Wang S., Jiang L., Kang J., Benraiss A., Harrison-Restelli C., Fraser R. A. R., Couldwell W. T., Kawaguchi A., Okano H., Nedergaard M., Goldman S. A., In vitro neurogenesis by progenitor cells isolated from the adult human hippocampus Nature Medicine 2000 6 3 271 277
116. Doetsch F., Caille I., Lim D. A., Garcia-Verdugo J. M., Alvarez-Buylla A., Subventricular zone astrocytes are neural stem cells in the adult mammalian brain Cell 1999 97 6 703 716
117. Morshead C. M., Reynolds B. A., Craig C. G., McBurney M. W., Staines W. A., Morassutti D., Weiss S., Van der Kooy D., Neural stem cells in the adult mammalian forebrain: a relatively quiescent subpopulation of subependymal cells Neuron 1994 13 5 1071 1082
118. Liu D.-Z., Ander B. P., Xu H., Shen Y., Kaur P., Deng W., Sharp F. R., Blood-brain barrier breakdown and repair by Src after thrombin-induced injury Annals of Neurology 2010 67 4 526 533
119. Becker S., A computational principle for hippocampal learning and neurogenesis Hippocampus 2005 15 6 722 738
120. Aimone J. B., Wiles J., Gage F. H., Potential role for adult neurogenesis in the encoding of time in new memories Nature Neuroscience 2006 9 6 723 727
121. Fallon J., Reid S., Kinyamu R., Opole I., Opole R., Baratta J., Korc M., Endo T. L., Duong A., Nguyen G., Karkehabadhi M., Twardzik D., Loughlin S., In vivo induction of massive proliferation, directed migration, and differentiation of neural cells in the adult mammalian brain Proceedings of the National Academy of Sciences of the United States of America 2000 97 26 14686 14691
122. Schneider L. S., Dagerman K. S., Higgins J. P. T., McShane R., Lack of evidence for the efficacy of memantine in mild Alzheimer disease Archives of Neurology 2011 68 8 991 998
123. Suzuki M., Nelson A. D., Eickstaedt J. B., Wallace K., Wright L. S., Svendsen C. N., Glutamate enhances proliferation and neurogenesis in human neural progenitor cell cultures derived from the fetal cortex European Journal of Neuroscience 2006 24 3 645 653
124. Zhang X., Yeung E. D., Wang J., Panzhinskiy E. E., Tong C., Li W., Li J., Isoliquiritigenin, a natural anti-oxidant, selectively inhibits the proliferation of prostate cancer cells Clinical and Experimental Pharmacology and Physiology 2010 37 8 841 847
125. Abe K., Neuroprotective therapy for ischemic stroke with free radical scavenger and gene-stem cell therapy Clinical Neurology 2008 48 11 896 898
126. Wang C. X., Shuaib A., Neuroprotective effects of free radical scavengers in stroke Drugs and Aging 2007 24 7 537 546
127. Eerman K., Brodaty H., Tocopherol (vitamin E) in Alzheimer's disease and other neurodegenerative disorders CNS Drugs 2004 18 12 807 825
128. Via J., Lloret A., Ort R., Alonso D., Molecular bases of the treatment of Alzheimer's disease with antioxidants: prevention of oxidative stress Molecular Aspects of Medicine 2004 25 1-2 117 123
129. Park K. W., Jin B. K., Thrombin-induced oxidative stress contributes to the death of hippocampal neurons: role of neuronal NADPH oxidase Journal of Neuroscience Research 2008 86 5 1053 1063
130. Levy G., Kaufmann P., Buchsbaum R., Montes J., Barsdorf A., Arbing R., Battista V., Zhou X., Mitsumoto H., Levin B., Thompson J. L. P., A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS Neurology 2006 66 5 660 663
131. Ferrante K. L., Shefner J., Zhang H., Betensky R., O'Brien M., Yu H., Fantasia M., Taft J., Beal M. F., Traynor B., Newhall K., Donofrio P., Caress J., Ashburn C., Freiberg B., O'Neill C., Paladenech C., Walker T., Pestronk A., Abrams B., Florence J., Renna R., Schierbecker J., Malkus B., Cudkowicz M., Tolerance of high-dose (3,000mg/day) coenzyme Q10 in ALS Neurology 2005 65 11 1834 1836
132. Yoshino H., Kimura A., Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotrophic Lateral Sclerosis 2006 7 4 241 245
133. Ito H., Wate R., Zhang J., Ohnishi S., Kaneko S., Ito H., Nakano S., Kusaka H., Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice Experimental Neurology 2008 213 2 448 455
134. Yuan W. J., Yasuhara T., Shingo T., Muraoka K., Agari T., Kameda M., Uozumi T., Tajiri N., Morimoto T., Jing M., Baba T., Wang F., Leung H., Matsui T., Miyoshi Y., Date I., Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons BMC Neuroscience 2008 9, article 75
135. Tanabe M., Nagatani Y., Saitoh K., Takasu K., Ono H., Pharmacological assessments of nitric oxide synthase isoforms and downstream diversity of NO signaling in the maintenance of thermal and mechanical hypersensitivity after peripheral nerve injury in mice Neuropharmacology 2009 56 3 702 708
136. Vanella L., Di Giacomo C., Acquaviva R., Santangelo R., Cardile V., Barbagallo I., Abraham N. G., Sorrenti V., The DDAH/NOS pathway in human prostatic cancer cell lines: antiangiogenic effect of L-NAME International Journal of Oncology 2011 39 5 1303 1310
137. Lee D. Y., Park K. W., Jin B. K., Thrombin induces neurodegeneration and microglial activation in the cortex in vivo and in vitro: proteolytic and non-proteolytic actions Biochemical and Biophysical Research Communications 2006 346 3 727 738
138. Sabichi A. L., Lee J. J., Grossman H. B., A randomized controlled trial of celecoxib to prevent recurrence of non-muscle-invasive bladder cancer Cancer Prevention Research 2011 4 10 1580 1589
139. Koch A., Bergman B., Holmberg E., Sederholm C., Ek L., Kosieradzki J., Lamberg K., Thaning L., Ydreborg S.-O., Srenson S., Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group European Journal of Cancer 2011 47 10 1546 1555
140. Gridelli C., Gallo C., Ceribelli A., Gebbia V., Gamucci T., Ciardiello F., Carozza F., Favaretto A., Daniele B., Galetta D., Barbera S., Rosetti F., Rossi A., Maione P., Cognetti F., Testa A., Di Maio M., Morabito A., Perrone F., Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study Lancet Oncology 2007 8 6 500 512
141. Kao J., Genden E. M., Chen C.-T., Rivera M., Tong C. C.L., Misiukiewicz K., Gupta V., Gurudutt V., Teng M., Packer S. H., Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer Cancer 2011 117 14 3173 3181
142. Lipton A., Campbell-Baird C., Witters L., Harvey H., Ali S., Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer Journal of Clinical Gastroenterology 2010 44 4 286 288
143. Antonarakis E. S., Heath E. I., Walczak J. R., Nelson W. G., Fedor H., De Marzo A. M., Zahurak M. L., Piantadosi S., Dannenberg A. J., Gurganus R. T., Baker S. D., Parnes H. L., DeWeese T. L., Partin A. W., Carducci M. A., Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers Journal of Clinical Oncology 2009 27 30 4986 4993
144. Fabi A., Metro G., Papaldo P., Mottolese M., Melucci E., Carlini P., Sperduti I., Russillo M., Gelibter A., Ferretti G., Tomao S., Milella M., Cognetti F., Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation Cancer Chemotherapy and Pharmacology 2008 62 4 717 725
145. Midgley R. S., McConkey C. C., Johnstone E. C., Dunn J. A., Smith J. L., Grumett S. A., Julier P., Iveson C., Yanagisawa Y., Warren B., Langman M. J., Kerr D. J., Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial Journal of Clinical Oncology 2010 28 30 4575 4580
146. Youns M., Efferth T., Hoheisel J. D., Transcript profiling identifies novel key players mediating the growth inhibitory effect of NS-398 on human pancreatic cancer cells European Journal of Pharmacology 2011 650 1 170 177
147. Fernndez-Martnez A. B., Bajo A. M., Valdehita A., Isabel Arenas M., Snchez-Chapado M., Carmena M. J., Prieto J. C., Multifunctional role of VIP in prostate cancer progression in a xenograft model: suppression by curcumin and COX-2 inhibitor NS-398 Peptides 2009 30 12 2357 2364
148. Zhang L., Tu J., Yu Z.-L., Wu Y.-D., Xu C.-M., Zhang S.-T., Effects of the inhibition of cyclooxygenase-2 on human esophageal cancer cells: inhibition of cell proliferation and induction of apoptosis Pathology and Oncology Research 2010 16 1 39 45
149. Banu N., Buda A., Chell S., Elder D., Moorghen M., Paraskeva C., Qualtrough D., Pignatelli M., Inhibition of COX-2 with NS-398 decreases colon cancer cell motility through blocking epidermal growth factor receptor transactivation: possibilities for combination therapy Cell Proliferation 2007 40 5 768 779
150. Warner T. D., Mitchell J. A., Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic FASEB Journal 2004 18 7 790 804
151. Etminan M., Gill S., Samii A., Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies British Medical Journal 2003 327 7407 128 131
152. Heo J. H., Seo H. N., Choe Y. J., Kim S., Oh C. R., Kim Y. D., Rhim H., Choo D. J., Kim J., Lee J. Y., T-type Ca2+ channel blockers suppress the growth of human cancer cells Bioorganic and Medicinal Chemistry Letters 2008 18 14 3899 3901
153. Franke C. L., Palm R., Dalby M., Schoonderwaldt H. C., Hantson L., Eriksson B., Lang-Jenssen L., Smakman J., Flunarizine in stroke treatment (FIST): a double-blind, placebo-controlled trial in Scandinavia and the Netherlands Acta Neurologica Scandinavica 1996 93 1 56 60
154. North W. G., Gao G., Memoli V. A., Pang R. H., Lynch L., Breast cancer expresses functional NMDA receptors Breast Cancer Research and Treatment 2010 122 2 307 314
155. Yang H., Chopp M., Jiang F., Zhang X., Schallert T., Interruption of functional recovery by the NMDA glutamate antagonist MK801 after compression of the sensorimotor cortex: implications for treatment of tumors or other mass-related brain injuries Experimental Neurology 2006 200 1 262 266
156. Andrews J., Amyotrophic lateral sclerosis: clinical management and research update Current Neurology and Neuroscience Reports 2009 9 1 59 68
157. McIntosh T. K., Smith D. H., Voddi M., Perri B. R., Stutzmann J.-M., Riluzole, a novel neuroprotective agent, attenuates both neurologic motor and cognitive dysfunction following experimental brain injury in the rat Journal of Neurotrauma 1996 13 12 767 780
158. Belayev L., Alonso O. F., Liu Y., Chappell A. S., Zhao W., Ginsberg M. D., Busto R., Talampanel, a novel noncompetitive AMPA antagonist, is neuroprotective after traumatic brain injury in rats Journal of Neurotrauma 2001 18 10 1031 1038
159. Kitzman P. H., Effectiveness of riluzole in suppressing spasticity in the spinal cord injured rat Neuroscience Letters 2009 455 2 150 153
160. Ardizzone T. D., Lu A., Wagner K. R., Tang Y., Ran R., Sharp F. R., Glutamate receptor blockade attenuates glucose hypermetabolism in perihematomal brain after experimental intracerebral hemorrhage in rat Stroke 2004 35 11 2587 2591
161. Meden P., Overgaard K., Sereghy T., Boysen G., Enhancing the efficacy of thrombolysis by AMPA receptor blockade with NBQX in a rat embolic stroke model Journal of the Neurological Sciences 1993 119 2 209 216
162. Watanabe K., Kanno T., Oshima T., Miwa H., Tashiro C., Nishizaki T., The NMDA receptor NR2A subunit regulates proliferation of MKN45 human gastric cancer cells Biochemical and Biophysical Research Communications 2008 367 2 487 490
163. Danysz W., Parsons C. G., The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence International Journal of Geriatric Psychiatry 2003 18 1 S23 S32
164. Molinuevo J. L., Llad A., Rami L., Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias American Journal of Alzheimer's Disease and other Dementias 2005 20 2 77 85
165. Robinson D. M., Keating G. M., Memantine: a review of its use in Alzheimer's disease Drugs 2006 66 11 1515 1534
166. Iraqi A., Hughes T. L., Nightmares and memantine: a case report and review of literature Journal of the American Medical Directors Association 2009 10 1 77 78
167. Zdanys K., Tampi R. R., A systematic review of off-label uses of memantine for psychiatric disorders Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008 32 6 1362 1374
168. Raghavendra Rao V. L., Dogan A., Todd K. G., Bowen K. K., Dempsey R. J., Neuroprotection by memantine, a non-competitive NMDA receptor antagonist after traumatic brain injury in rats Brain Research 2001 911 1 96 100
169. Lee S.-T., Chu K., Jung K.-H., Kim J., Kim E.-H., Kim S.-J., Sinn D.-I., Ko S.-Y., Kim M., Roh J.-K., Memantine reduces hematoma expansion in experimental intracerebral hemorrhage, resulting in functional improvement Journal of Cerebral Blood Flow and Metabolism 2006 26 4 536 544
170. Babu C. S., Ramanathan M., Pre-ischemic treatment with memantine reversed the neurochemical and behavioural parameters but not energy metabolites in middle cerebral artery occluded rats Pharmacology Biochemistry and Behavior 2009 92 3 424 432
171. Yu L., Garg H. G., Li B., Linhardt R. J., Hales C. A., Antitumor effect of butanoylated heparin with low anticoagulant activity on lung cancer growth in mice and rats Current Cancer Drug Targets 2010 10 2 229 241
172. Mikulk R., Dufek M., Goldemund D., Reif M., A pilot study on systemic thrombolysis followed by low molecular weight heparin in ischemic stroke European Journal of Neurology 2006 13 10 1106 1111
173. Sun Z., Zhao Z., Zhao S., Sheng Y., Zhao Z., Gao C., Li J., Liu X., Recombinant hirudin treatment modulates aquaporin-4 and aquaporin-9 expression after intracerebral hemorrhage in vivo Molecular Biology Reports 2009 36 5 1119 1127
174. Xue M., Hollenberg M. D., Yong V. W., Combination of thrombin and matrix metalloproteinase-9 exacerbates neurotoxicity in cell culture and intracerebral hemorrhage in mice Journal of Neuroscience 2006 26 40 10281 10291
175. Goerge T., Barg A., Schnaeker E. M., Poppelmann B., Shpacovitch V., Rattenholl A., Maaser C., Luger T. A., Steinhoff M., Schneider S. W., Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation Cancer Research 2006 66 15 7766 7774
176. Junge C. E., Sugawara T., Mannaioni G., Alagarsamy S., Conn P. J., Brat D. J., Chan P. H., Traynelis S. F., The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia Proceedings of the National Academy of Sciences of the United States of America 2003 100 22 13019 13024
177. Hamill C. E., Caudle W. M., Richardson J. R., Yuan H., Pennell K. D., Greene J. G., Miller G. W., Traynelis S. F., Exacerbation of dopaminergic terminal damage in a mouse model of Parkinson's disease by the G-protein-coupled receptor protease-activated receptor 1 Molecular Pharmacology 2007 72 3 653 664
178. Acosta M. T., Kardel P. G., Walsh K. S., Rosenbaum K. N., Gioia G. A., Packer R. J., Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase I study Pediatric Neurology 2011 45 4 241 245
179. Knox J. J., Siu L. L., Chen E., Dimitroulakos J., Kamel-Reid S., Moore M. J., Chin S., Irish J., LaFramboise S., Oza A. M., A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix European Journal of Cancer 2005 41 4 523 530
180. Barkan B., Starinsky S., Friedman E., Stein R., Kloog Y., The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1 Clinical Cancer Research 2006 12 18 5533 5542
181. Bjrkhem-Bergman L., Acimovic J., Torndal U. B., Parini P., Eriksson L. C., Lovastatin prevents carcinogenesis in a rat model for liver cancer. Effects of ubiquinone supplementation Anticancer Research 2010 30 4 1105 1112
182. Martirosyan A., Clendening J. W., Goard C. A., Penn L. Z., Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance BMC Cancer 2010 10, article 103
183. Klawitter J., Shokati T., Moll V., Christians U., Klawitter J., Effects of lovastatin on breast cancer cells: a proteo-metabonomic study Breast Cancer Research 2010 12 2, article R16
184. Lee J., Lee I., Park C., Kang W. K., Lovastatin-induced RhoA modulation and its effect on senescence in prostate cancer cells Biochemical and Biophysical Research Communications 2006 339 3 748 754
185. Park I. H., Kim J. Y., Jung J. I., Han J. Y., Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations Investigational New Drugs 2010 28 6 791 799
186. Elkind M. S. V., Sacco R. L., Macarthur R. B., Fink D. J., Peerschke E., Andrews H., Neils G., Stillman J., Corporan T., Leifer D., Cheung K., The Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART): an adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischemic stroke International Journal of Stroke 2008 3 3 210 218
187. Elkind M. S. V., Sacco R. L., MacArthur R. B., Peerschke E., Neils G., Andrews H., Stillman J., Corporan T., Leifer D., Liu R., Cheung K., High-dose lovastatin for acute ischemic stroke: results of the phase I dose escalation Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART) Cerebrovascular Diseases 2009 28 3 266 275
188. Smirnova I. V., Citron B. A., Arnold P. M., Festoff B. W., Neuroprotective signal transduction in model motor neurons exposed to thrombin: G-protein modulation effects on neurite outgrowth, Ca2+ mobilization, and apoptosis Journal of Neurobiology 2001 48 2 87 100
189. Cunningham D. D., Thrombin induces apoptosis in cultured neurons and astrocytes via a pathway requiring tyrosine kinase and RhoA activities Journal of Neuroscience 1997 17 14 5316 5326
190. Herold C. I., Chadaram V., Peterson B. L., Marcom P. K., Hopkins J., Kimmick G. G., Favaro J., Hamilton E., Welch R. A., Bacus S., Blackwell K. L., Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing Clinical Cancer Research 2011 17 18 6061 6070
191. Gucalp A., Sparano J. A., Caravelli J., Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer Clinical Breast Cancer 2011 11 5 306 311
192. Anbalagan M., Carrier L., Glodowski S., Hangauer D., Shan B., Rowan B. G., KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor alpha positive breast cancer. Breast Cancer Research and Treatment. In press
193. Pohorelic B., Singh R., Parkin S., Role of Src in breast cancer cell migration and invasion in a breast cell/bone-derived cell microenvironment. Breast Cancer Research and Treatment. In press
194. Ceppi P., Rapa I., Lo Iacono M., Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer. International Journal of Cancer. In press
195. Krystal G. W., DeBerry C. S., Linnekin D., Litz J., Lck associates with and is activated by kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1 Cancer Research 1998 58 20 4660 4666
196. Kong L., Deng Z., Shen H., Zhang Y., Src family kinase inhibitor PP2 efficiently inhibits cervical cancer cell proliferation through down-regulating phospho-Src-Y416 and phospho-EGFR-Y1173 Molecular and Cellular Biochemistry 2011 348 1-2 11 19
197. Fujimoto E., Sato H., Nagashima Y., Negishi E., Shirai S., Fukumoto K., Hagiwara H., Hagiwara K., Ueno K., Yano T., A Src family inhibitor (PP1) potentiates tumor-suppressive effect of connexin 32 gene in renal cancer cells Life Sciences 2005 76 23 2711 2720
198. Li L., Ren C. H., Tahir S. A., Ren C., Thompson T. C., Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A Molecular and Cellular Biology 2003 23 24 9389 9404
199. Ardizzone T. D., Zhan X., Ander B. P., Sharp F. R., Src kinase inhibition improves acute outcomes after experimental intracerebral hemorrhage Stroke 2007 38 5 1621 1625
200. Siddiqui I. A., Asim M., Hafeez B. B., Adhami V. M., Tarapore R. S., Mukhtar H., Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer FASEB Journal 2011 25 4 1198 1207
201. Sen T., Dutta A., Chatterjee A., Epigallocatechin-3-gallate (EGCG) downregulates gelatinase-B (MMP-9) by involvement of FAK/ERK/NF B and AP-1 in the human breast cancer cell line MDA-MB-231 Anti-Cancer Drugs 2010 21 6 632 644
202. Milligan S. A., Burke P., Coleman D. T., Bigelow R. L., Steffan J. J., Carroll J. L., Williams B. J., Cardelli J. A., The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells Clinical Cancer Research 2009 15 15 4885 4894
203. Shankar S., Ganapathy S., Hingorani S. R., Srivastava R. K., EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer Frontiers in Bioscience 2008 13 2 440 452
204. Faderl S., Ferrajoli A., Harris D., Van Q., Priebe W., Estrov Z., WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML) Anticancer Research 2005 25 3 B 1841 1850
205. Shakoori A., Mai W., Miyashita K., Yasumoto K., Takahashi Y., Ooi A., Kawakami K., Minamoto T., Inhibition of GSK-3 activity attenuates proliferation of human colon cancer cells in rodents Cancer Science 2007 98 9 1388 1393
206. Pizarro J. G., Folch J., Esparza J. L., Jordan J., Palls M., Camins A., A molecular study of pathways involved in the inhibition of cell proliferation in neuroblastoma B65 cells by the GSK-3 inhibitors lithium and SB-415286 Journal of Cellular and Molecular Medicine 2009 13 9 B 3906 3917
207. Palls M., Camins A., Molecular and biochemical features in Alzheimer's disease Current Pharmaceutical Design 2006 12 33 4389 4408
208. Bhat R. V., Budd Haeberlein S. L., Avila J., Glycogen synthase kinase 3: a drug target for CNS therapies Journal of Neurochemistry 2004 89 6 1313 1317
209. Cross D. A. E., Culbert A. A., Chalmers K. A., Facci L., Skaper S. D., Reith A. D., Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death Journal of Neurochemistry 2001 77 1 94 102
210. Jope R. S., Johnson G. V. W., The glamour and gloom of glycogen synthase kinase-3 Trends in Biochemical Sciences 2004 29 2 95 102
211. Dunn N., Holmes C., Mullee M., Does lithium therapy protect against the onset of dementia? Alzheimer Disease and Associated Disorders 2005 19 1 20 22
212. Su Y., Ryder J., Li B., Wu X., Fox N., Solenberg P., Brune K., Paul S., Zhou Y., Liu F., Ni B., Lithium, a common drug for bipolar disorder treatment, regulates amyloid- precursor protein processing Biochemistry 2004 43 22 6899 6908
213. Chung E. S., Bok E., Sohn S., Lee Y. D., Baik H. H., Jin B. K., GT1b-induced neurotoxicity is mediated by the Akt/GSK-3/tau signaling pathway but not caspase-3 in mesencephalic dopaminergic neurons BMC Neuroscience 2010 11, article 74
214. Jiang H., Guo W., Liang X., Rao Y., Both the establishment and the maintenance of neuronal polarity require active mechanisms: critical roles of GSK-3 and its upstream regulators Cell 2005 120 1 123 135
215. Fornai F., Longone P., Cafaro L., Kastsiuchenka O., Ferrucci M., Manca M. L., Lazzeri G., Spalloni A., Bellio N., Lenzi P., Modugno N., Siciliano G., Isidoro C., Murri L., Ruggieri S., Paparelli A., Lithium delays progression of amyotrophic lateral sclerosis Proceedings of the National Academy of Sciences of the United States of America 2008 105 6 2052 2057
216. Leung E., Kim J. E., Rewcastle G. W., Finlay G. J., Baguley B. C., Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells Cancer Biology and Therapy 2011 11 11 938 946
217. Zhao L., Teter B., Morihara T., Lim G. P., Ambegaokar S. S., Ubeda O. J., Frautschy S. A., Cole G. M., Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention Journal of Neuroscience 2004 24 49 11120 11126
218. Kim S.-N., Kim S.-T., Doo A.-R., Park J.-Y., Moon W., Chae Y., Yin C. S., Lee H., Park H.-J., Phosphatidylinositol 3-kinase/Akt signaling pathway mediates acupuncture-induced dopaminergic neuron protection and motor function improvement in a mouse model of parkinson's disease International Journal of Neuroscience 2011 121 10 562 569
219. Van Ummersen L., Binger K., Volkman J., Marnocha R., Tutsch K., Kolesar J., Arzoomanian R., Alberti D., Wilding G., A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer Clinical Cancer Research 2004 10 22 7450 7456
220. Pal S. K., Reckamp K., Yu H., Figlin R. A., Akt inhibitors in clinical development for the treatment of cancer Expert Opinion on Investigational Drugs 2010 19 11 1355 1366
221. (19952011) FDA Approved Drugs for Oncology. http://www.centerwatch.com/ drug-information/fda-approvals/drug-areas.aspx?AreaID=12
222. Behbakht K., Sill M. W., Darcy K. M., Rubin S. C., Mannel R. S., Waggoner S., Schilder R. J., Cai K. Q., Godwin A. K., Alpaugh R. K., Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies. A Gynecologic Oncology Group study Gynecologic Oncology 2011 123 1 19 26
223. Oza A. M., Elit L., Tsao M.-S., Kamel-Reid S., Biagi J., Provencher D. M., Gotlieb W. H., Hoskins P. J., Ghatage P., Tonkin K. S., Mackay H. J., Mazurka J., Sederias J., Ivy P., Dancey J. E., Eisenhauer E. A., Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group Journal of Clinical Oncology 2011 29 24 3278 3285
224. Chan S., Scheulen M. E., Johnston S., Mross K., Cardoso F., Dittrich C., Eiermann W., Hess D., Morant R., Semiglazov V., Borner M., Salzberg M., Ostapenko V., Illiger H. J., Behringer D., Bardy-Bouxin N., Boni J., Kong S., Cincotta M., Moore L., Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer Journal of Clinical Oncology 2005 23 23 5314 5322
225. Galanis E., Buckner J. C., Maurer M. J., Kreisberg J. I., Ballman K., Boni J., Peralba J. M., Jenkins R. B., Dakhil S. R., Morton R. F., Jaeckle K. A., Scheithauer B. W., Dancey J., Hidalgo M., Walsh D. J., Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a north central cancer treatment group study Journal of Clinical Oncology 2005 23 23 5294 5304
226. Duran I., Kortmansky J., Singh D., Hirte H., Kocha W., Goss G., Le L., Oza A., Nicklee T., Ho J., Birle D., Pond G. R., Arboine D., Dancey J., Aviel-Ronen S., Tsao M. S., Hedley D., Siu L. L., A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas British Journal of Cancer 2006 95 9 1148 1154
227. Pandya K. J., Dahlberg S., Hidalgo M., Cohen R. B., Lee M. W., Schiller J. H., Johnson D. H., A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500) Journal of Thoracic Oncology 2007 2 11 1036 1041
228. Gerullis H., Ecke T. H., Janusch B., Arndt C., Heidari M., Oniani J., Otto T., Long-term response in advanced bladder cancer involving the use of temsirolimus and vinflunine after platin resistance Anti-Cancer Drugs 2011 22 9 940 943
229. Zardavas D., Meisel A., Samaras P., Knuth A., Renner C., Pestalozzi B. C., Stenner-Liewen F., Temsirolimus is highly effective as third-line treatment in chromophobe renal cell cancer Case Reports in Oncology 2011 4 1 16 18
230. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., Staroslawska E., Sosman J., McDermott D., Bodrogi I., Kovacevic Z., Lesovoy V., Schmidt-Wolf I. G. H., Barbarash O., Gokmen E., O'Toole T., Lustgarten S., Moore L., Motzer R. J., Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma New England Journal of Medicine 2007 356 22 2271 2281
231. Spilman P., Podlutskaya N., Hart M. J., Debnath J., Gorostiza O., Bredesen D., Richardson A., Strong R., Galvan V., Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid- levels in a mouse model of alzheimer's disease PLoS ONE 2010 5 4, article e9979
232. Malagelada C., Jin Z. H., Jackson-Lewis V., Przedborski S., Greene L. A., Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease Journal of Neuroscience 2010 30 3 1166 1175
233. Chen S., Atkins C. M., Liu C. L., Alonso O. F., Dietrich W. D., Hu B. R., Alterations in mammalian target of rapamycin signaling pathways after traumatic brain injury Journal of Cerebral Blood Flow and Metabolism 2007 27 5 939 949
234. Park J., Zhang J., Qiu J., Zhu X., Degterev A., Lo E. H., Whalen M. J., Combination therapy targeting Akt and mammalian target of rapamycin improves functional outcome after controlled cortical impact in mice. Journal of Cerebral Blood Flow and Metabolism. In press
235. Codeluppi S., Svensson C. I., Hefferan M. P., Valencia F., Silldorff M. D., Oshiro M., Marsala M., Pasquale E. B., The Rheb-mTOR pathway is upregulated in reactive astrocytes of the injured spinal cord Journal of Neuroscience 2009 29 4 1093 1104
236. Sekiguchi A., Kanno H., Ozawa H., Yamaya S., Itoi E., Rapamycin Promotes Autophagy and Reduces Neural Tissue Damage and Locomotor Impairment after Spinal Cord Injury in Mice. Journal of Neurotrauma. In press
237. Chauhan A., Sharma U., Jagannathan N. R., Reeta K. H., Gupta Y. K., Rapamycin protects against middle cerebral artery occlusion induced focal cerebral ischemia in rats Behavioural Brain Research 2011 225 2 603 609
238. Jimeno A., Hallur G., Chan A., Zhang X., Cusatis G., Chan F., Shah P., Chen R., Hamel E., Garrett-Mayer E., Khan S., Hidalgo M., Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer Molecular Cancer Therapeutics 2007 6 5 1509 1516
239. TauRx-Therapeutics-Ltd, TRx0014 in Patients With Mild or Moderate Alzheimer's Disease. ClinicalTrials.gov Identifier: NCT00515333. 2007, http://clinicaltrials.gov/ct2/show/NCT00515333?spons= 22TauRx+Therapeutics+Ltd22sponsex=Yrank=1
240. Williams M., Progress in Alzheimer's disease drug discovery: an update Current Opinion in Investigational Drugs 2009 10 1 23 34
241. Zelivianski S., Spellman M., Kellerman M., Kakitelashvilli V., Zhou X. W., Lugo E., Lee M. S., Taylor R., Davis T. L., Hauke R., Lin M. F., ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells International Journal of Cancer 2003 107 3 478 485
242. Yong H. H., Hwa J. M., You B. R., Yang Y. M., Sung Z. K., Suhn H. K., Woo H. P., The MEK inhibitor PD98059 attenuates growth inhibition and death in gallic acid-treated Calu-6 lung cancer cells by preventing glutathione depletion Molecular Medicine Reports 2010 3 3 519 524
243. Lim S. J., Lee Y. J., Lee E., p38MAPK inhibitor SB203580 sensitizes human SNU-C4 colon cancer cells to exisulind-induced apoptosis Oncology Reports 2006 16 5 1131 1135
244. Karunakaran S., Saeed U., Mishra M., Valli R. K., Joshi S. D., Meka D. P., Seth P., Ravindranath V., Selective activation of p38 mitogen-activated protein kinase in dopaminergic neurons of substantia nigra leads to nuclear translocation of p53 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice Journal of Neuroscience 2008 28 47 12500 12509
245. Barone F. C., Irving E. A., Ray A. M., Lee J. C., Kassis S., Kumar S., Badger A. M., Legos J. J., Erhardt J. A., Ohlstein E. H., Hunter A. J., Harrison D. C., Philpott K., Smith B. R., Adams J. L., Parsons A. A., Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia Medicinal Research Reviews 2001 21 2 129 145
246. Martial S., Giorgelli J.-L., Renaudo A., Derijard B., Soriani O., SP600125 inhibits Kv channels through a JNK-independent pathway in cancer cells Biochemical and Biophysical Research Communications 2008 366 4 944 950
247. Kim J.-H., Kim T. H., Kang H. S., Ro J., Kim H. S., Yoon S., SP600125, an inhibitor of Jnk pathway, reduces viability of relatively resistant cancer cells to doxorubicin Biochemical and Biophysical Research Communications 2009 387 3 450 455
248. Wang L. H., Besirli C. G., Johnson E. M. Jr., Mixed-lineage kinases: a target for the prevention of neurodegeneration Annual Review of Pharmacology and Toxicology 2004 44 451 474
249. Leszek J., Inglot A. D., Janusz M., Byczkiewicz F., Kiejna A., Georgiades J., Lisowski J., Colostrinin proline-rich polypeptide complex from ovine colostruma long-term study of its efficacy in Alzheimer's disease Medical Science Monitor 2002 8 10 PI93 PI96
250. Kuan C. Y., Burke R. E., Targeting the JNK signaling pathway for stroke and parkinson's diseases therapy Current Drug Targets 2005 4 1 63 67